Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided immunosuppression optimization in living-donor kidney transplantation
NL-OMON49228Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of antithymocyte globulin, basiliximab, tacrolimus, mycophenolate mofetil and prednisone in kidney transplant (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite efficacy endpoint. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
antithymocyte globulinbasiliximabtacrolimusmycophenolate mofetilprednisone
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON49228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49228.